Please use this identifier to cite or link to this item:
|Title:||Evolution of androgen deprivation therapy|
|Citation:||Cancer Forum, 2015; 39(3):189-194|
|Publisher:||The Cancer Council Australia|
|Ganesh V Raj, Luke A Selth, Tanya K Day, Wayne D Tilley|
|Abstract:||The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/ or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signallingtargeted therapies in clinical development.|
|Keywords:||Cancer--mortality; androgens--therapeutic use; prostate--cancer--patients; androgens--receptors|
|Rights:||© Cancer Council of Australia|
|Appears in Collections:||Aurora harvest 8|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.